EGFR and non-small cell lung carcinoma: In previous studies, dacomitinib has shown higher anticancer effects in terms of progression-free survival and response periods than gefitinib in the primary treatment of EGFR mutant-positive NSCLC patients [51,52] and has demonstrated clinical activity in recurrent/metastatic cranial squamous cell carcinoma (RM-SCCHN) [53].